Business
Aclarion sells Nociscan, a cloud-based SaaS platform using magnetic resonance spectroscopy data, signal processing, biomarkers, and augmented intelligence to help identify painful lumbar discs.
Aclarion added revenue from a tiny base, but cash burn stayed far larger than Nociscan sales.
The read at a glance✓ Audited against SEC data
- Business mix — Nociscan spine SaaS diagnosticsNote
- Revenue — Revenue +65.6% to $75.7KOK
- Profitability — Net loss widened to $7.2MWatch
- Cash burn — Free cash flow was -$7.2MWatch
- Balance sheet — Equity rose to $12.8MOK
- Insiders — 2 buys / 0 sells; $5K boughtNote
- Accounting — Altman-Z grey; EQ greyWatch
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-04
- 10-Q · Quarterly report2026-05-13
- DEF 14A · Annual proxy (pay & governance)2026-04-27
- 8-K · Company announcement2026-04-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aclarion, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.